Intrinsic value of Dentsply Sirona - XRAY

Previous Close

$38.67

  Intrinsic Value

$21.57

stock screener

  Rating & Target

sell

-44%

Previous close

$38.67

 
Intrinsic value

$21.57

 
Up/down potential

-44%

 
Rating

sell

We calculate the intrinsic value of XRAY stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 8.9

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  6.60
  6.44
  6.30
  6.17
  6.05
  5.94
  5.85
  5.77
  5.69
  5.62
  5.56
  5.50
  5.45
  5.41
  5.37
  5.33
  5.30
  5.27
  5.24
  5.22
  5.19
  5.18
  5.16
  5.14
  5.13
  5.11
  5.10
  5.09
  5.08
  5.08
Revenue, $m
  4,257
  4,531
  4,816
  5,113
  5,422
  5,745
  6,081
  6,431
  6,797
  7,179
  7,578
  7,995
  8,431
  8,887
  9,364
  9,863
  10,385
  10,932
  11,505
  12,105
  12,734
  13,393
  14,083
  14,807
  15,567
  16,363
  17,198
  18,074
  18,993
  19,957
Variable operating expenses, $m
  3,689
  3,879
  4,077
  4,283
  4,498
  4,722
  4,955
  5,198
  5,452
  5,718
  5,260
  5,550
  5,853
  6,169
  6,500
  6,846
  7,209
  7,589
  7,986
  8,403
  8,839
  9,297
  9,776
  10,279
  10,806
  11,359
  11,938
  12,547
  13,184
  13,853
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  3,689
  3,879
  4,077
  4,283
  4,498
  4,722
  4,955
  5,198
  5,452
  5,718
  5,260
  5,550
  5,853
  6,169
  6,500
  6,846
  7,209
  7,589
  7,986
  8,403
  8,839
  9,297
  9,776
  10,279
  10,806
  11,359
  11,938
  12,547
  13,184
  13,853
Operating income, $m
  568
  652
  739
  830
  924
  1,023
  1,126
  1,233
  1,345
  1,461
  2,318
  2,445
  2,578
  2,718
  2,864
  3,016
  3,176
  3,343
  3,518
  3,702
  3,894
  4,096
  4,307
  4,528
  4,761
  5,004
  5,260
  5,527
  5,808
  6,103
EBITDA, $m
  2,257
  2,402
  2,553
  2,711
  2,875
  3,046
  3,224
  3,410
  3,604
  3,806
  4,018
  4,239
  4,470
  4,712
  4,965
  5,229
  5,506
  5,796
  6,100
  6,418
  6,752
  7,101
  7,467
  7,851
  8,254
  8,676
  9,119
  9,583
  10,070
  10,581
Interest expense (income), $m
  37
  89
  102
  116
  130
  145
  161
  177
  194
  212
  231
  250
  270
  292
  314
  337
  361
  386
  413
  441
  470
  500
  532
  566
  601
  638
  676
  717
  759
  803
  850
Earnings before tax, $m
  479
  550
  623
  699
  779
  862
  948
  1,038
  1,132
  1,231
  2,067
  2,175
  2,287
  2,404
  2,527
  2,655
  2,789
  2,930
  3,078
  3,232
  3,394
  3,564
  3,741
  3,928
  4,123
  4,328
  4,543
  4,768
  5,005
  5,253
Tax expense, $m
  129
  148
  168
  189
  210
  233
  256
  280
  306
  332
  558
  587
  617
  649
  682
  717
  753
  791
  831
  873
  916
  962
  1,010
  1,060
  1,113
  1,169
  1,227
  1,287
  1,351
  1,418
Net income, $m
  350
  401
  455
  511
  569
  629
  692
  758
  827
  898
  1,509
  1,587
  1,669
  1,755
  1,844
  1,938
  2,036
  2,139
  2,247
  2,359
  2,478
  2,601
  2,731
  2,867
  3,010
  3,159
  3,316
  3,481
  3,654
  3,835

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  11,056
  11,768
  12,509
  13,280
  14,084
  14,921
  15,794
  16,704
  17,655
  18,647
  19,683
  20,766
  21,898
  23,082
  24,321
  25,617
  26,974
  28,394
  29,882
  31,441
  33,074
  34,786
  36,580
  38,461
  40,433
  42,501
  44,670
  46,945
  49,332
  51,836
Adjusted assets (=assets-cash), $m
  11,056
  11,768
  12,509
  13,280
  14,084
  14,921
  15,794
  16,704
  17,655
  18,647
  19,683
  20,766
  21,898
  23,082
  24,321
  25,617
  26,974
  28,394
  29,882
  31,441
  33,074
  34,786
  36,580
  38,461
  40,433
  42,501
  44,670
  46,945
  49,332
  51,836
Revenue / Adjusted assets
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
  0.385
Average production assets, $m
  9,552
  10,167
  10,807
  11,473
  12,167
  12,891
  13,645
  14,432
  15,253
  16,110
  17,005
  17,941
  18,919
  19,942
  21,012
  22,132
  23,304
  24,531
  25,817
  27,163
  28,574
  30,053
  31,603
  33,228
  34,932
  36,718
  38,592
  40,558
  42,620
  44,783
Working capital, $m
  362
  385
  409
  435
  461
  488
  517
  547
  578
  610
  644
  680
  717
  755
  796
  838
  883
  929
  978
  1,029
  1,082
  1,138
  1,197
  1,259
  1,323
  1,391
  1,462
  1,536
  1,614
  1,696
Total debt, $m
  1,885
  2,143
  2,411
  2,691
  2,981
  3,285
  3,601
  3,930
  4,274
  4,633
  5,008
  5,401
  5,810
  6,239
  6,687
  7,157
  7,648
  8,162
  8,701
  9,265
  9,856
  10,476
  11,125
  11,806
  12,520
  13,269
  14,054
  14,877
  15,741
  16,648
Total liabilities, $m
  4,002
  4,260
  4,528
  4,807
  5,098
  5,401
  5,717
  6,047
  6,391
  6,750
  7,125
  7,517
  7,927
  8,356
  8,804
  9,273
  9,765
  10,279
  10,817
  11,382
  11,973
  12,593
  13,242
  13,923
  14,637
  15,385
  16,171
  16,994
  17,858
  18,764
Total equity, $m
  7,054
  7,508
  7,981
  8,473
  8,985
  9,520
  10,076
  10,657
  11,264
  11,897
  12,558
  13,249
  13,971
  14,726
  15,517
  16,344
  17,209
  18,116
  19,065
  20,059
  21,101
  22,193
  23,338
  24,538
  25,796
  27,116
  28,500
  29,951
  31,474
  33,071
Total liabilities and equity, $m
  11,056
  11,768
  12,509
  13,280
  14,083
  14,921
  15,793
  16,704
  17,655
  18,647
  19,683
  20,766
  21,898
  23,082
  24,321
  25,617
  26,974
  28,395
  29,882
  31,441
  33,074
  34,786
  36,580
  38,461
  40,433
  42,501
  44,671
  46,945
  49,332
  51,835
Debt-to-equity ratio
  0.270
  0.290
  0.300
  0.320
  0.330
  0.350
  0.360
  0.370
  0.380
  0.390
  0.400
  0.410
  0.420
  0.420
  0.430
  0.440
  0.440
  0.450
  0.460
  0.460
  0.470
  0.470
  0.480
  0.480
  0.490
  0.490
  0.490
  0.500
  0.500
  0.500
Adjusted equity ratio
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638
  0.638

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  350
  401
  455
  511
  569
  629
  692
  758
  827
  898
  1,509
  1,587
  1,669
  1,755
  1,844
  1,938
  2,036
  2,139
  2,247
  2,359
  2,478
  2,601
  2,731
  2,867
  3,010
  3,159
  3,316
  3,481
  3,654
  3,835
Depreciation, amort., depletion, $m
  1,689
  1,751
  1,815
  1,881
  1,951
  2,023
  2,098
  2,177
  2,259
  2,345
  1,701
  1,794
  1,892
  1,994
  2,101
  2,213
  2,330
  2,453
  2,582
  2,716
  2,857
  3,005
  3,160
  3,323
  3,493
  3,672
  3,859
  4,056
  4,262
  4,478
Funds from operations, $m
  2,039
  2,152
  2,270
  2,392
  2,519
  2,652
  2,791
  2,935
  3,086
  3,243
  3,210
  3,382
  3,561
  3,749
  3,946
  4,151
  4,367
  4,592
  4,828
  5,076
  5,335
  5,607
  5,891
  6,190
  6,503
  6,831
  7,176
  7,537
  7,916
  8,313
Change in working capital, $m
  22
  23
  24
  25
  26
  27
  29
  30
  31
  32
  34
  35
  37
  39
  41
  42
  44
  46
  49
  51
  53
  56
  59
  62
  65
  68
  71
  74
  78
  82
Cash from operations, $m
  2,017
  2,129
  2,245
  2,367
  2,493
  2,625
  2,762
  2,905
  3,055
  3,211
  3,176
  3,346
  3,524
  3,710
  3,905
  4,109
  4,322
  4,546
  4,780
  5,025
  5,282
  5,551
  5,833
  6,128
  6,439
  6,764
  7,105
  7,462
  7,838
  8,231
Maintenance CAPEX, $m
  -896
  -955
  -1,017
  -1,081
  -1,147
  -1,217
  -1,289
  -1,364
  -1,443
  -1,525
  -1,611
  -1,701
  -1,794
  -1,892
  -1,994
  -2,101
  -2,213
  -2,330
  -2,453
  -2,582
  -2,716
  -2,857
  -3,005
  -3,160
  -3,323
  -3,493
  -3,672
  -3,859
  -4,056
  -4,262
New CAPEX, $m
  -589
  -615
  -640
  -666
  -694
  -723
  -754
  -787
  -821
  -857
  -895
  -936
  -978
  -1,023
  -1,070
  -1,120
  -1,172
  -1,227
  -1,285
  -1,347
  -1,411
  -1,479
  -1,550
  -1,625
  -1,704
  -1,787
  -1,874
  -1,966
  -2,062
  -2,163
Cash from investing activities, $m
  -1,485
  -1,570
  -1,657
  -1,747
  -1,841
  -1,940
  -2,043
  -2,151
  -2,264
  -2,382
  -2,506
  -2,637
  -2,772
  -2,915
  -3,064
  -3,221
  -3,385
  -3,557
  -3,738
  -3,929
  -4,127
  -4,336
  -4,555
  -4,785
  -5,027
  -5,280
  -5,546
  -5,825
  -6,118
  -6,425
Free cash flow, $m
  531
  558
  589
  620
  652
  685
  719
  754
  791
  828
  669
  710
  752
  796
  841
  888
  937
  988
  1,041
  1,096
  1,154
  1,214
  1,277
  1,343
  1,412
  1,484
  1,559
  1,638
  1,720
  1,806
Issuance/(repayment) of debt, $m
  244
  258
  268
  279
  291
  303
  316
  330
  344
  359
  375
  392
  410
  429
  448
  469
  491
  514
  539
  564
  591
  620
  649
  681
  714
  749
  785
  824
  864
  906
Issuance/(repurchase) of shares, $m
  88
  53
  18
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  332
  311
  286
  279
  291
  303
  316
  330
  344
  359
  375
  392
  410
  429
  448
  469
  491
  514
  539
  564
  591
  620
  649
  681
  714
  749
  785
  824
  864
  906
Total cash flow (excl. dividends), $m
  863
  869
  875
  899
  942
  988
  1,035
  1,084
  1,135
  1,188
  1,045
  1,102
  1,162
  1,224
  1,289
  1,357
  1,428
  1,502
  1,580
  1,661
  1,745
  1,834
  1,927
  2,024
  2,126
  2,232
  2,344
  2,461
  2,584
  2,712
Retained Cash Flow (-), $m
  -438
  -454
  -473
  -492
  -513
  -534
  -557
  -581
  -606
  -633
  -661
  -691
  -722
  -755
  -790
  -827
  -866
  -906
  -949
  -994
  -1,042
  -1,092
  -1,145
  -1,200
  -1,258
  -1,319
  -1,384
  -1,451
  -1,523
  -1,597
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  48
  51
  54
  58
  61
  65
  69
  73
  77
  82
  86
  91
  96
  101
  107
  112
  118
  125
  131
  138
  145
  153
  161
  169
  178
  187
  196
  206
  217
  228
Cash available for distribution, $m
  425
  415
  402
  407
  430
  454
  478
  503
  528
  555
  383
  411
  439
  469
  499
  530
  562
  596
  630
  666
  703
  742
  782
  824
  868
  913
  960
  1,010
  1,061
  1,115
Discount rate, %
  4.40
  4.62
  4.85
  5.09
  5.35
  5.62
  5.90
  6.19
  6.50
  6.83
  7.17
  7.53
  7.90
  8.30
  8.71
  9.15
  9.60
  10.08
  10.59
  11.12
  11.67
  12.26
  12.87
  13.51
  14.19
  14.90
  15.64
  16.43
  17.25
  18.11
PV of cash for distribution, $m
  407
  379
  349
  333
  331
  327
  320
  311
  300
  287
  179
  172
  164
  154
  143
  131
  118
  106
  93
  81
  69
  58
  48
  39
  31
  25
  19
  14
  11
  8
Current shareholders' claim on cash, %
  99.0
  98.5
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3
  98.3

DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies. The dental industry encompasses the diagnosis, treatment and prevention of disease and ailments of the teeth, gums and supporting bone. Its principal dental product categories are dental consumable products, dental laboratory products, dental specialty products and dental equipment. Additionally, its consumable medical device products are used for urological and surgical applications. These products are produced by the Company in the United States and internationally and are distributed throughout the world under various brand names, including ANKYLOS, AQUASIL ULTRA, ARTICADENT, ATLANTIS, CALIBRA, CAULK, CAVITRON, CELTRA, DELTON, DENTSPLY, DETREY and DYRACT.

FINANCIAL RATIOS  of  Dentsply Sirona (XRAY)

Valuation Ratios
P/E Ratio 20.7
Price to Sales 2.4
Price to Book 1.1
Price to Tangible Book
Price to Cash Flow 15.8
Price to Free Cash Flow 20.4
Growth Rates
Sales Growth Rate 40.1%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 75%
Cap. Spend. - 3 Yr. Gr. Rate 4.5%
Financial Strength
Quick Ratio 18
Current Ratio 0
LT Debt to Equity 18.6%
Total Debt to Equity 18.9%
Interest Coverage 13
Management Effectiveness
Return On Assets 5.8%
Ret/ On Assets - 3 Yr. Avg. 6.6%
Return On Total Capital 6.5%
Ret/ On T. Cap. - 3 Yr. Avg. 7.4%
Return On Equity 8.2%
Return On Equity - 3 Yr. Avg. 10.8%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 53.4%
Gross Margin - 3 Yr. Avg. 55%
EBITDA Margin 20%
EBITDA Margin - 3 Yr. Avg. 19.6%
Operating Margin 12.1%
Oper. Margin - 3 Yr. Avg. 13.8%
Pre-Tax Margin 11.8%
Pre-Tax Margin - 3 Yr. Avg. 12.6%
Net Profit Margin 11.5%
Net Profit Margin - 3 Yr. Avg. 10.6%
Effective Tax Rate 2.3%
Eff/ Tax Rate - 3 Yr. Avg. 15.2%
Payout Ratio 15.1%

XRAY stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the XRAY stock intrinsic value calculation we used $3993 million for the last fiscal year's total revenue generated by Dentsply Sirona. The default revenue input number comes from 2017 income statement of Dentsply Sirona. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our XRAY stock valuation model: a) initial revenue growth rate of 6.6% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.4%, whose default value for XRAY is calculated based on our internal credit rating of Dentsply Sirona, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Dentsply Sirona.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of XRAY stock the variable cost ratio is equal to 87.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for XRAY stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Dentsply Sirona.

Corporate tax rate of 27% is the nominal tax rate for Dentsply Sirona. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the XRAY stock is equal to 1.2%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for XRAY are equal to 224.4%.

Life of production assets of 10 years is the average useful life of capital assets used in Dentsply Sirona operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for XRAY is equal to 8.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $6616 million for Dentsply Sirona - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 229 million for Dentsply Sirona is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Dentsply Sirona at the current share price and the inputted number of shares is $8.9 billion.

RELATED COMPANIES Price Int.Val. Rating
ALGN Align Technolo 357.30 242.71  hold
BIOL Biolase 1.78 0.09  str.sell
MLSS Milestone Scie 0.750 0.07  str.sell
DHR Danaher 100.71 56.60  sell
MMM 3M 204.77 175.63  hold

COMPANY NEWS

▶ Stocks That Fell to 3-Year Lows in the Week of Aug. 17   [Aug-18-18 11:33AM  GuruFocus.com]
▶ Dentsply: 2Q Earnings Snapshot   [06:40AM  Associated Press]
▶ The 3 Worst Healthcare Stocks of 2018 (So Far)   [Jul-19-18 08:46AM  Motley Fool]
▶ The 5 Worst S&P 500 Stocks of 2018 (So Far)   [Jul-18-18 09:17AM  Motley Fool]
▶ These 3 Value Stocks Are Absurdly Cheap Right Now   [Jul-06-18 06:25AM  Motley Fool]
▶ Dentsply Sirona Declares Quarterly Cash Dividend   [Jun-26-18 05:30PM  GlobeNewswire]
▶ Is It Time To Buy DENTSPLY SIRONA Inc (NASDAQ:XRAY)?   [Jun-25-18 02:23PM  Simply Wall St.]
▶ Athenahealth, Exxon rise; Cognizant, Dentsply fall   [May-07-18 04:33PM  Associated Press]
▶ Dentsply: 1Q Earnings Snapshot   [05:04AM  Associated Press]
▶ Dentsply Sirona Reports First Quarter 2018 Results   [May-06-18 07:30PM  GlobeNewswire]
▶ Al Gore's Firm Is Buying These Two Stocks   [Apr-26-18 03:12PM  Barrons.com]
▶ Dentsply Sirona Declares Quarterly Cash Dividend   [Apr-25-18 05:15PM  GlobeNewswire]
▶ New Strong Sell Stocks for March 19th   [Mar-19-18 08:16AM  Zacks]
▶ Ruane Cunniff Comments on Dentsply Sirona   [Mar-06-18 05:42PM  GuruFocus.com]
▶ Dentsply reports 4Q loss   [Mar-01-18 08:03PM  Associated Press]
▶ Daniel Loeb's Top 10 Holdings of 4th Quarter   [Feb-19-18 05:57PM  GuruFocus.com]
▶ Daniel Loeb's Top 10 Holdings of 4th Quarter   [05:49PM  GuruFocus.com]
▶ Dentsply Sirona Declares Quarterly Cash Dividend   [Feb-14-18 05:00PM  GlobeNewswire]
▶ Juno and Boeing climb while Goldman Sachs and GE drop   [Jan-17-18 04:35PM  Associated Press]
▶ Why eBay and Dentsply Sirona Fell on January 10   [Jan-12-18 09:02AM  Market Realist]
▶ Wall Street Issues Majority Buy Ratings on Align Technology   [Jan-03-18 10:32AM  Market Realist]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.